



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

002.00190 (DUNW/P22561US)

1644/11

Applicant: Muimo et al.)
Serial No.: 09/944,030)
Filed: August 31, 2001)
For: METHODS OF DETERMINING ALTERED)
NDPK FUNCTIONS AND THE)
DIAGNOSIS OF CYSTIC FIBROSIS)

Examiner: P. Nolan
Art Unit: 1644

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Restriction Requirement dated February 10, 2004, applicants elect the invention of Group I (claims 1-13 and 51) without traverse.

Applicants further elect a species, with traverse, disclosed in claim 7, nucleoside diphosphate kinase (NDPK) function. Applicants submit that the requirement for an election of species is improper, because the species do not exceed a reasonable number and a search of the generic claim includes such few species that a search and examination of all of the species would not impose a serious burden. Claim 7 is a generic claim and claims 7 and 9-13 are readable on the species.

Respectfully submitted,

May 10, 2004

Date

Karla M. Weyand

Karla M. Weyand
Registration No. 40,223

Rogalskyj & Weyand, LLP
P.O. Box 44
Livonia, New York 14487-0044
Tel: 716-626-5380
Fax: 716-626-5384

I hereby certify that this document is being deposited with the U.S. Postal Service as first class mail on 5/10/04 under 37 CFR 1.8 and is addressed to the Commissioner for Patent, PO Box 1450, Alexandria, VA 22313-1450

Karla M. Weyand
Signature of Person Mailing Correspondence

Karla M. Weyand
Typed Name of Person Mailing Correspondence